TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant and Adjuvant Chemotherapy in High-risk Soft Tissue Sarcoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Soft tissue sarcoma histology~* Tumor size \>= 5 cm~* Deep/extracompartimental localization~* Grade 2/3 (FNCLCC)~* Patients with inadequate previous therapy~* Age 18-65 years~* normal bone marrow function~* normal liver function~* normal renal function~* Karnofsky index \>=80%~Exclusion Criteria:~* Chordoma~* Chondrosarcoma~* Kaposi´ sarcoma~* Neuroblastoma~* Mesothelioma~* Osteosarcoma/Ewings´sarcoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): All patients receive 4 cycles of EIA chemotherapy pre- and postoperatively. There is no further observation arm. The study is non-randomized.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment-naïve choroidal neovascularization (CNV) secondary to age-related macular degeneration (nAMD) in the study eye~* Ability to comply with the study protocol, in the investigator's judgment~* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use acceptable contraceptive measures that result in failure rate \<1% per year during the treatment period and for at least 3 months after the final dose of study treatment~* Other protocol-specified inclusion criteria may apply~Exclusion Criteria:~* Uncontrolled blood pressure, defined as systolic blood pressure \>180 millimeters of mercury (mmHg) and/or diastolic blood pressure \>100 mmHg while a patient is at rest on Day 1~* Pregnancy or breastfeeding, or intention to become pregnant during the study~* CNV due to causes other than AMD in the study eye~* Any history of macular pathology unrelated to AMD affecting vision or contributing to the presence of intraretinal or subretinal fluid in the study eye~* Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could either reduce the potential for visual improvement or require medical or surgical intervention during the study~* Uncontrolled glaucoma in the study eye~* Any prior or concomitant treatment for CNV or vitreomacular-interface abnormalities in the study eye~* Prior IVT administration of faricimab in either eye~* History of idiopathic or autoimmune-associated uveitis in either eye~* Active ocular inflammation or suspected or active ocular or periocular infection in either eye~* Other protocol-specified exclusion criteria may apply

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Faricimab (Type: EXPERIMENTAL): None
- Arm B: Aflibercept (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ketamine for Low Mood States in the ER

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adults (\>18yrs) presenting to the Emergency department with symptoms of depression and/or suicide ideation (MADRS\>30) with ability to give informed consent.~* medically stable~Exclusion Criteria:~* psychosis, bipolar, or other significant physical or mental illness~* pregnancy~* non-voluntary status~* urine drug screen positive for drugs of abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: EXPERIMENTAL): Patients were administered a single sub-anaesthetic i.v. bolus of ketamine (0.2 mg/kg over 1-2 min) in the ED, with continuous monitoring of vital signs, adverse events and psychotomimetic side-effects for 4 h post-administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed prostate adenocarcinoma~* Bone metastases confirmed by bone scan~* Current androgen deprivation therapy~* Castration-resistant disease based on progression in bone and/or PSA progression~* Recovered from toxicities related to prior treatment, except alopecia, lymphopenia, other non-clinically significant adverse events~* Life expectancy of greater than 3 months~* Normal organ and marrow function~* Capable of understanding and complying with the protocol requirements~* Agree to use medically accepted methods of contraception~* Able to swallow capsules~Exclusion Criteria:~* More than two prior chemotherapy regimens for metastatic prostate cancer~* Known untreated, symptomatic or uncontrolled brain metastases~* Serious or unhealed wound~* Treatment with anticoagulants~* Previously identified allergy or hypersensitivity to components of the study treatment formulation~* History of a different malignancy unless disease-free for at least 5 years, or basal or squamous cell carcinoma of the skin~* Current antiretroviral therapy~* Uncontrolled hypertension~* Uncontrolled intercurrent illness

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Dose level 0: cabozantinib 40 mg daily
- Cohort 2 (Type: EXPERIMENTAL): Dose level -1: cabozantinib 20 mg daily
- Expansion cohort (Type: EXPERIMENTAL): Dose level 0: cabozantinib 40 mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing User Experience of Different Delivery Devices for Glucagon

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All participants (Trained Users, Participants with Diabetes \[PWDs\] and Untrained Users):~* Are able to understand the purpose and procedure of the study and to give written informed consent to show willingness to participate in the study~Trained Users only:~* Are participants who are not diagnosed with Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM)~* Are close friends/relatives of a patient with T1DM or T2DM on insulin~* Have not previously administered any rescue medications (e.g. epinephrine, glucagon, narcan or seizure medications)~Untrained Users only:~* Have not been diagnosed with T1DM or T2DM, and are not a Trained User of a person with T1DM or T2DM~* Have not previously administered any rescue medications (e.g. epinephrine, glucagon, narcan or seizure medications)~Exclusion Criteria:~All participants (Trained Users, PWDs and Untrained Users):~* In the opinion of the investigator or sponsor, are unsuitable for inclusion in the study~Trained Users and Untrained Users only (i.e. the participants involved in the simulations):~* Are currently enrolled in a clinical study involving any type of medical research judged not to be scientifically or medically compatible with this study~* Are judged by the investigator as being likely to have difficulty performing the administration due to physical, cognitive and/or severe psychiatric disorder~* Are judged by the investigator as being trained or experienced in performing rescue drug administration~* Are judged by the investigator as being trained or experienced in performing high-fidelity simulations of drug administration~* Have received formal training in a medical field, and/or worked in this field within the prior 5 years; or otherwise are judged by the investigator as being trained or experienced as a first responder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Nasal Glucagon Device (NG) (Type: EXPERIMENTAL): Empty NG device administered to a manikin during simulations of severe hypoglycaemia emergencies. No drug will be administered to humans.
- Glucagon Emergency Kit (GEK) (Type: ACTIVE_COMPARATOR): Commercially available GEK delivered intramuscularly to a manikin during simulations of severe hypoglycaemia emergencies. No drug will be administered to humans.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Donors After Circulatory Death Heart Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Donor Inclusion~* Maastricht Category III DCD donor, defined as expected death after the withdrawal of life- supportive therapy (WLST)~* Donor age 18-49 years old inclusive~* Warm ischemic time (WIT) ≤ 30 mins, with warm ischemic time defined as: Time from when mean systolic blood pressure (SBP) is \< 50 mmHg or peripheral saturation \< 70% to aortic cross-clamp and administration of cold cardioplegia in the donor.~Donor Exclusion~* Previous cardiac surgery~* Known coronary artery disease~* Cardiogenic shock or myocardial infarction, or~* Sustained terminal ejection fraction (EF) of ≤ 50%, or~* Significant valve disease except for competent bicuspid aortic valve~Recipient Inclusion~* Primary heart transplant candidates~* Age ≥ 18 years old~* Signed: (1) written informed consent document; (2) authorization to use and disclose protected health information; and (3) consent to TransMedics' use of recipients' United Network for Organ Sharing (UNOS)/Organ Procurement and Transplantation Network (OPTN) data and recipients' Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) data.~Recipient Exclusion~* Prior solid organ or bone marrow transplant~* Chronic use of hemodialysis or diagnosis of chronic renal insufficiency~* Multi-organ transplant~* Investigator unwilling to randomize to either arm.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DCD Heart Possible (Type: EXPERIMENTAL): None
- Standard of Care Heart Only (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Promoting Heart Health in Preschool Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children attending one of the 14 H.I. in Usaquén~* Children who are 3, 4, or 5 years of age at the time of the beginning of the intervention~Exclusion Criteria:~* Unwillingness to provide informed consent~* Children who have received formal training in healthy habits in nutrition and / or physical activity in the 6 months prior to the start of the follow-up period of the study.~* Children who plan to receive formal training in healthy habits in nutrition and / or physical activity during the follow-up study period.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 5 Years
- Healthy Volunteers: t

Study Arms:
- Children-Multicomponent intervention (Type: EXPERIMENTAL): The intervened children were provided classroom educational and playful activities during 5 months, which included Sesame Workshop Healthy Habits storybooks, posters, videos, games, and songs (1 hour daily); a Healthy family day workshop (1 hour); and weekly health notes. Parents participated in 3 workshops and weekly notes containing positive health messages about nutrition and active lifestyles to share with their children. Teachers also participated in 3 centralized training sessions, plus personalized working sessions with a research supervisor (2 hours every 15 days), and received a teacher's guide.
- children - control group (Type: NO_INTERVENTION): The control preschool facilities continued with their usual preschool curriculum

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SMART: Somatotrophics, Memory, and Aging Research Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to give and understand informed consent~* Able to communicate in English~* No exclusionary criteria apply~* Age between 55 and 90 years~* Independent in their daily living abilities~* Living at home with a reliable spouse, significant other or caregiver~* Normal PSA (for men) or mammogram (for women) within one year of study entry~The following inclusion criteria will be applied to identify potential MCI participants:~* Memory complaint that can be corroborated by a study partner~* Memory test scores meeting the diagnostic criteria for MCI~* MMSE score greater than 20~The following inclusion criteria will be applied to identify potential normal control participants:~* Cognitive testing does not indicate MCI~* MMSE score greater than 28~Exclusion Criteria:~* Use of medications known to affect the GHRH/GH/IGF-I axis, including transdermal estrogens (use of oral estrogens is not contraindicated)~* Significant medical illness or organ failure, such as uncontrolled hypertension, diabetes, cardiac disease, cerebrovascular disease, chronic obstructive pulmonary disease, kidney and liver disease~* Significant neurologic disease that might affect cognition, such as Alzheimer's disease, stroke, Parkinson's disease, multiple sclerosis, severe head injury with loss of consciousness for more than 30 minutes or with permanent neurologic sequelae~* Personal or strong family history of cancer (especially colon, breast or melanoma)~* Evidence for pituitary disease by history or physical examination~* Symptoms or history of carpal tunnel or a positive Phalen's Test~* Active arthritis~* Significant current psychiatric illness, such as depression, schizophrenia or an Axis II diagnosis suggestive of an inability to successfully complete the study protocol~* Current use of an anti-psychotic, anti-depressant, anti-convulsant, anti-coagulant, anxiolytic or sedative~* Current or planned use of DHEA, testosterone or cognition-enhancing medication (e.g., cholinesterase inhibitors, memantine)~* Weight greater than 150% ideal body weight~* Tobacco use, excessive alcohol intake (more than 2 drinks per day), excessive caffeine intake (more than 4 cups of coffee per day)~* Baseline IGF-I level greater than the mid-range for healthy young adults (250 ng/ml)~* Meets NINCDS/ADRDA criteria for AD

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Totally Endoscopic Ablation of Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 50 years~2. Longstanding persistent AF of \> 1 year duration~3. Severe symptoms related to AF~4. Have signed and dated Informed Consent.~5. Willing and able to comply with the protocol for the duration of the trial.~Exclusion Criteria:~1. Severe ischemic heart disease or heart valve disease~2. Thrombus formation in left atrial appendage~3. Intolerance to warfarin medication~4. Advanced pulmonary disease, FEV 1 \< 1.5 litre~5. Left atrial diameter \> 60 mm~6. Body Mass Index (BMI) \> 35 kg/m2~7. Previous pulmonary or heart surgery~8. Participation in another clinical trial within the last 30 days prior to enrollment

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Endoscopic ablation of atrial fibrillation (Type: EXPERIMENTAL): None
- Rate control (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible for this protocol, subjects must:~1. Be at least 10 kg of body weight.~2. Have a confirmed diagnosis of HAE.~3. Have an acute HAE attack and be able to initiate treatment within 8 hours after onset of symptoms.~Exclusion Criteria:~To be eligible for this protocol, subjects must not:~1. Have any active infectious illness.~2. Have had a prior HAE attack and/or received any C1 INH product within 7 days prior to dosing with study drug.~3. Have received therapy with antifibrinolytics (e.g., tranexamic acid), androgens (e.g., danazol, oxandrolone, stanozolol, or testosterone), ecallantide (Kalbitor®), or icatibant (Firazyr®) within 7 days prior to dosing with study drug.~4. Have a history of allergic reaction to C1 INH products, including CINRYZE (or any of the components of CINRYZE), or other blood products.~5. Have participated in any other investigational drug evaluation within 30 days prior to dosing with study drug, or have previously received treatment with CINRYZE in this study at any time.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- 500 U CINRYZE (10-25 kg body weight) (Type: EXPERIMENTAL): Single IV dose of 500 U CINRYZE
- 1000 U CINRYZE (10-25 kg body weight) (Type: EXPERIMENTAL): Single IV dose of 1000 U CINRYZE
- 1000 U CINRYZE (>25 kg body weight) (Type: EXPERIMENTAL): Single IV dose of 1000 U CINRYZE
- 1500 U CINRYZE (>25 kg body weight) (Type: EXPERIMENTAL): Single IV dose of 1500 U CINRYZE

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Meets current Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) diagnostic criteria for AD and demonstrates serious behavioral problems; diagnosis confirmed by Autism, Diagnostic Interview-Revised (ADI-R).~* CGI score \> = 4 AND an ABC Irritability/Agitation subscale score \> = 18 at screening and baseline (randomization)~* Mental age of at least 18 months~* Male or female 6 to 17 years of age inclusive, at the time of randomization~Exclusion Criteria:~* Patients considered treatment resistant to neuroleptic medication based on lack of therapeutic response to 2 different neuroleptics after treatment of at least 3 weeks each~* Patients previously treated and not responding to aripiprazole treatment~* The patient is currently diagnosed with another disorder on the autism spectrum, including PDD-NOS, Asperger's Disorder, Rett's Disorder, Fragile-X Syndrome or Childhood Disintegrative Disorder~* Current diagnosis of bipolar disorder, psychosis, schizophrenia, or major depression~* A seizure in the past year~* History of severe head trauma or stroke~* Non-pharmacologic therapy (e.g., psychotherapy, behavior modification) should be stable prior to screening and consistent throughout the study

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- A1 (Type: EXPERIMENTAL): 5 mg
- A2 (Type: EXPERIMENTAL): 10 mg
- A3 (Type: EXPERIMENTAL): 15 mg
- B1 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete